Project SIRT6 Activator
ConditionAging
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age50-80
SponsorNational University of Singapore
About this trial
The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process could prevent or delay multiple diseases, enhancing healthspan. Fucoidan, a sulfated polysaccharide from brown macroalgae, is a safe dietary supplement with Sirtuin-6 (SIRT6) activating properties, which are linked to longevity. Clinical studies have shown that it reduces inflammatory markers associated with biological aging and frailty and influences DNA methylation in vitro and in vivo; however, its effects on human DNA methylation remain unknown.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
50-80 years males;
Resident of Singapore (citizenship or permanent residency is not required);
Prefrail according to Fried frailty phenotype score;
English-literate who can understand, read and write in English;
Disqualifiers
Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke, peripheral vascular disease);
Current cancer or non-stable chronic obstructive pulmonary disease (COPD);
Use of anticoagulant medication;
Consuming seaweed more than 3 times a week;
Trial design
Design model
Parallel
Treatments tested in this trial
Fucoidan
Dietary supplementEligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.
Placebo
Dietary supplementEligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: SIRT6 activatorExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in blood DNA methylation status, years
DNA methylation aging clock
Time frame
from baseline to end of intervention (6 months)Secondary outcomes
1
Change in blood inflammatory markers (pg/mL)
comparison of inflammatory markers: IL-10, IFN-γ，IL-17, TNF-a, IL-6，CXCL9 (pg/mL) at baseline, interim and end-of-trial
Time frame
from baseline to end of intervention (6 months)2
Body Mass Index (BMI) change
comparison of BMI at baseline, interim and end of trial
Time frame
from baseline to end of intervention (6 months)3
Waist-to-hip ratio change
comparison of waist-to-hip ratio at baseline, interim and end of trial
Time frame
from baseline to end of intervention (6 months)4
Body fat mass (kg) change
comparison of body fat mass at baseline, interim and end of trial
Time frame
from baseline to end of intervention (6 months)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
National University of Singapore
Lead sponsor
University of Rochester
Collaborator
L'Oreal
Collaborator
DoNotAge.org
Collaborator
Source ClinicalTrials.gov